AR and posterior cortical atrophy: Conventional ADT is the most common agent for neoadjuvant therapy, since PCa is largely androgen-driven, and androgen receptor is widely expressed throughout the course of the disease.[13] Neoadjuvant ADT therapy prior to RP for high-risk PCa has been proven to reduce positive margin rates, tumor volume, and lymph node invasion, but long-term benefits have not been observed, such as 5-year biochemical recurrence rate and cancer-related death.[13,14] The feasibility and preliminary efficiency of neoadjuvant chemotherapy plus ADT has also been proven.